Parents' Experience With a Mobile Health Intervention to Influence Human Papillomavirus Vaccination Decision Making: Mixed Methods Study.
HPV
HPV vaccine
adolescents
app
application
cervical cancer
human papillomavirus
mHealth
parent
parenting
pediatrics
sexual health
user experience
vaccination
vaccine
Journal
JMIR pediatrics and parenting
ISSN: 2561-6722
Titre abrégé: JMIR Pediatr Parent
Pays: Canada
ID NLM: 101727244
Informations de publication
Date de publication:
21 Feb 2022
21 Feb 2022
Historique:
received:
11
05
2021
accepted:
17
11
2021
revised:
25
10
2021
entrez:
21
2
2022
pubmed:
22
2
2022
medline:
22
2
2022
Statut:
epublish
Résumé
Human papillomavirus (HPV)-attributed cancers are preventable, yet HPV vaccination rates severely lag behind other adolescent vaccinations. HPVcancerFree (HPVCF) is a mobile health (mHealth) intervention developed to influence parental HPV vaccination decision making by raising awareness of HPV, reducing HPV vaccination barriers, and enabling HPV vaccination scheduling and reminders through a smartphone app. Evaluating the user experience of mHealth interventions is a vital component in assessing their quality and success but tends to be underreported in mHealth intervention evaluation. We aimed to evaluate the user experience of HPVCF, an HPV cancer prevention app designed for a pediatric clinic network, using mixed methods data collected from log files, survey measures, and qualitative feedback. Study data were evaluated from parents in a large US pediatric clinic network using HPVCF in the treatment study condition of a group randomized controlled trial. Log data captured HPVCF retention and use. Postintervention rating scales and items assessed HPVCF utility, usefulness, understandability, appeal, credibility, and perceived impact. Overall quality was evaluated using the user version of the Mobile Application Rating Scale (uMars). Open-ended responses assessed parent recommendations for HPVCF enhancement. The 98 parents were mainly female (n=94, 96%), 41 (5.67) years of age, college educated (n=55, 56%), and White and non-Hispanic (n=55, 56%) and had private health insurance for their children (n=75, 77%). Parents used HPVCF 197 times, with the average visit duration approximating 3.5 minutes. The uMARS app quality score was positively skewed (4.2/5.0). Mean ratings were highest for information (4.46 [SD 0.53]) and lowest for engagement (3.74 [SD 0.69]). In addition, of 95 parents, 45 (47%) rated HPVCF as helpful in HPV vaccination decision making and 16 (17%) attributed HPV vaccine initiation to HPVCF. Parents reported that HPVCF increased their awareness (84/95, 88%), knowledge (84/95, 88%), and HPV vaccination intentions (64/95, 67%). Most of the 98 parents rated the 4 HPVCF components as useful (72-92 [73%-94%]). Parents also agreed that HPVCF is clear (86/95, 91%), accurate (86/95, 91%), and more helpful than other HPV vaccine information they had received (89/95, 94%) and that they would recommend it to others (81/95, 85%). In addition, parents suggested ways to increase awareness and engagement with the app, along with opportunities to enhance the content and functionality. HPVCF was well received by parents and performed well on indicators of quality, usefulness, utility, credibility, and perceived impact. This study contributes a multimethod and multimeasure evaluation to the growing body of literature focused on assessing the user experience of patient-focused technology-mediated applications for HPV education.
Sections du résumé
BACKGROUND
BACKGROUND
Human papillomavirus (HPV)-attributed cancers are preventable, yet HPV vaccination rates severely lag behind other adolescent vaccinations. HPVcancerFree (HPVCF) is a mobile health (mHealth) intervention developed to influence parental HPV vaccination decision making by raising awareness of HPV, reducing HPV vaccination barriers, and enabling HPV vaccination scheduling and reminders through a smartphone app. Evaluating the user experience of mHealth interventions is a vital component in assessing their quality and success but tends to be underreported in mHealth intervention evaluation.
OBJECTIVE
OBJECTIVE
We aimed to evaluate the user experience of HPVCF, an HPV cancer prevention app designed for a pediatric clinic network, using mixed methods data collected from log files, survey measures, and qualitative feedback.
METHODS
METHODS
Study data were evaluated from parents in a large US pediatric clinic network using HPVCF in the treatment study condition of a group randomized controlled trial. Log data captured HPVCF retention and use. Postintervention rating scales and items assessed HPVCF utility, usefulness, understandability, appeal, credibility, and perceived impact. Overall quality was evaluated using the user version of the Mobile Application Rating Scale (uMars). Open-ended responses assessed parent recommendations for HPVCF enhancement.
RESULTS
RESULTS
The 98 parents were mainly female (n=94, 96%), 41 (5.67) years of age, college educated (n=55, 56%), and White and non-Hispanic (n=55, 56%) and had private health insurance for their children (n=75, 77%). Parents used HPVCF 197 times, with the average visit duration approximating 3.5 minutes. The uMARS app quality score was positively skewed (4.2/5.0). Mean ratings were highest for information (4.46 [SD 0.53]) and lowest for engagement (3.74 [SD 0.69]). In addition, of 95 parents, 45 (47%) rated HPVCF as helpful in HPV vaccination decision making and 16 (17%) attributed HPV vaccine initiation to HPVCF. Parents reported that HPVCF increased their awareness (84/95, 88%), knowledge (84/95, 88%), and HPV vaccination intentions (64/95, 67%). Most of the 98 parents rated the 4 HPVCF components as useful (72-92 [73%-94%]). Parents also agreed that HPVCF is clear (86/95, 91%), accurate (86/95, 91%), and more helpful than other HPV vaccine information they had received (89/95, 94%) and that they would recommend it to others (81/95, 85%). In addition, parents suggested ways to increase awareness and engagement with the app, along with opportunities to enhance the content and functionality.
CONCLUSIONS
CONCLUSIONS
HPVCF was well received by parents and performed well on indicators of quality, usefulness, utility, credibility, and perceived impact. This study contributes a multimethod and multimeasure evaluation to the growing body of literature focused on assessing the user experience of patient-focused technology-mediated applications for HPV education.
Identifiants
pubmed: 35188469
pii: v5i1e30340
doi: 10.2196/30340
pmc: PMC8902654
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e30340Informations de copyright
©Elisabeth RB Becker, Ross Shegog, Lara S Savas, Erica L Frost, Sharon P Coan, C Mary Healy, Stanley W Spinner, Sally W Vernon. Originally published in JMIR Pediatrics and Parenting (https://pediatrics.jmir.org), 21.02.2022.
Références
Ann Behav Med. 2020 Nov 1;54(11):805-826
pubmed: 32338719
Epilepsy Behav. 2018 Nov;88:218-226
pubmed: 30300871
Disabil Rehabil Assist Technol. 2021 Oct;16(7):712-721
pubmed: 31910687
JMIR Mhealth Uhealth. 2018 Jan 17;6(1):e23
pubmed: 29343463
Creat Educ. 2014 Aug;5(15):1428-1447
pubmed: 25705561
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
Vaccine. 2019 Jan 21;37(4):595-601
pubmed: 30580838
Health Educ Behav. 2019 Dec;46(2_suppl):12-19
pubmed: 31742453
Int Conf Pervasive Comput Technol Healthc. 2018 May;2018:360-366
pubmed: 30555731
JMIR Mhealth Uhealth. 2019 Apr 11;7(4):e11500
pubmed: 30973342
J Low Genit Tract Dis. 2019 Jul;23(3):188-192
pubmed: 30973442
Stud Health Technol Inform. 2022 Jun 6;290:819-823
pubmed: 35673132
MMWR Morb Mortal Wkly Rep. 2017 Aug 25;66(33):874-882
pubmed: 28837546
JMIR Mhealth Uhealth. 2017 Oct 04;5(10):e148
pubmed: 28978495
J Natl Cancer Inst. 2015 Apr 29;107(6):djv086
pubmed: 25925419
MMWR Morb Mortal Wkly Rep. 2019 Aug 23;68(33):718-723
pubmed: 31437143
J Med Internet Res. 2016 Dec 16;18(12):e317
pubmed: 27986647
J Pediatr Psychol. 2019 Apr 1;44(3):333-342
pubmed: 30358863
J Appl Gerontol. 2020 Jun;39(6):601-608
pubmed: 30049239
Am J Prev Med. 2016 Nov;51(5):843-851
pubmed: 27745684
JMIR Mhealth Uhealth. 2020 Jul 8;8(7):e15896
pubmed: 32673237
J Am Med Inform Assoc. 2018 Aug 1;25(8):1089-1098
pubmed: 29788283
AMIA Jt Summits Transl Sci Proc. 2020 May 30;2020:43-52
pubmed: 32477622
JMIR Form Res. 2021 Nov 19;5(11):e28846
pubmed: 34806991
Addict Behav. 2018 Feb;77:89-95
pubmed: 28992580
JMIR Serious Games. 2019 Apr 08;7(2):e8540
pubmed: 30958271
Patient Educ Couns. 2017 Apr;100(4):736-741
pubmed: 27912928
Hum Vaccin Immunother. 2017 Mar 4;13(3):680-686
pubmed: 27763818
JMIR Mhealth Uhealth. 2019 May 1;7(5):e13019
pubmed: 31066712
J Pediatr Nurs. 2019 Jan - Feb;44:31-41
pubmed: 30683279
J Appl Res Child. 2019;10(2):
pubmed: 34231977
Cureus. 2019 Feb 20;11(2):e4104
pubmed: 31057998
Stud Health Technol Inform. 2007;129(Pt 2):983-7
pubmed: 17911862
NPJ Digit Med. 2020 May 21;3:74
pubmed: 32509971
J Med Internet Res. 2015 Jan 30;17(1):e30
pubmed: 25639757
JMIR Mhealth Uhealth. 2016 Jun 10;4(2):e72
pubmed: 27287964
Prev Med. 2020 Feb;131:105968
pubmed: 31881235
Transl Behav Med. 2020 Dec 31;10(6):1538-1548
pubmed: 31328775
Online J Commun Media Technol. 2015 Oct;5(4):184-203
pubmed: 26594313
Stud Health Technol Inform. 2019;257:17-23
pubmed: 30741166
Sensors (Basel). 2019 Jan 21;19(2):
pubmed: 30669657
MMWR Morb Mortal Wkly Rep. 2019 Aug 23;68(33):724-728
pubmed: 31437140
JMIR Mhealth Uhealth. 2015 Mar 11;3(1):e27
pubmed: 25760773
JMIR Mhealth Uhealth. 2018 Jan 05;6(1):e4
pubmed: 29305343
Am J Prev Med. 2016 Dec;51(6):1051-1059
pubmed: 27659122
J Mob Technol Med. 2017 Apr;6(1):39-45
pubmed: 29104674
World J Urol. 2018 Apr;36(4):565-573
pubmed: 29222595